FMP

FMP

Enter

OYST - Oyster Point Pharma, Inc.

Profile of Oyster Point Pharma, Inc.(OYST), As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, I

About

ceo

Dr. Jeffrey Nau

sector

Healthcare

industry

Biotechnology

website

https://www.oysterpointrx.com

exchange

NASDAQ

Description

As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

CIK

0001720725

ISIN

US69242L1061

CUSIP

69242L106

Address

202 Carnegie Ctr Ste 109

Phone

16093829032

Country

US

Employee

303

IPO Date

Oct 31, 2019

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep